Interchangeable & Unbranded Biologics: Cutting Through The Confusion presented at ASAP by Melissa Krause
PHSL Vice President Melissa Krause presented at the American Society for Automation in Pharmacy (ASAP) 2022 Annual Conference. Melissa’s presentation discussed different perspectives on interchangeable biologics, addressed how interchangeable biologics and unbranded biologics are being displayed in pharmacy management systems, and included recommendation on what pharmacists need to cut through confusion and ensure correct dispensing and reimbursement.
Click here to view Melissa’s presentation slides.
Poll Results
February 2023 Question of the Month
Do you feel like your organization understands the FDA’s Draft Guidance for Industry on Drug Importation?
We have reviewed the guidance and are taking a watch and wait approach: 75%
We have reviewed the guidance and are taking proactive steps to act on it: 25%
We have reviewed the guidance but do not feel like it will impact our organization: 0%
Not familiar/We have not reviewed the guidance: 0%
January 2023 Question of the Month
How will payers manage reimbursement of multiple interchangeable biosimilars?
MAC reimbursement: 10%
Generic non-MAC reimbursement rate: 10%
Brand reimbursement rate: 40%
Specialty drug specific rate: 40%
Average Sales Price (ASP): 0%
Average Manufacturer Price (AMP): 0%
National Average Drug Acquisition Cost (NADAC): 0%
December 2022 Question of the Month
In which area could you or your company most benefit from additional training?
Biosimilars and interchangeability requirements: 46.1%
Dynamics that drive PBM and health plan decisions: 15.4%
Various hurdles a prescription must clear before being dispensed: 15.4%
Changing 340B landscape: 15.4%
Flow of funds and prescriptions through the pharmacy channels: 7.7%
Pharmacy chain initiatives and strategy updates: 0%
Contact
968 Perry Highway
Pittsburgh, PA 15237
Get Directions »
Phone: (412) 635-4650
Follow/Subscribe:
